Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities
Neuroblastoma is the most common extracranial pediatric solid tumor. Although the incorporation of anti-GD2 immunotherapy into standard care has improved outcomes, five-year survival for high-risk patients remains below 50%. This highlights that, while…